Table 3.
Number of cases (n), prevalence (%), relative risk (RR) and 95% CI of self-reported medical conditions, according to eating disorder status in Binge Eating in Rio Survey (n = 2297), 2020
| Clinical comorbiditya | BED n = 29 | BN n = 17 | RBE n = 90 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 | ||||||||||
| N (%) | RR | 95% CI | RR | 95% CI | N (%) | RR | 95% CI | RR | 95% CI | N (%) | RR | 95% CI | RR | 95% CI | |
| Arterial hypertension | 9 (38.0) | 2.5 | 0.8–7.6 | 1.7 | 0.6–5.4 | 4 (7.1) | 0.31 | 0.82–1.16 | 0.2 | 0.04–0.61 | 24 (19.8) | 1.0 | 0.56–1.78 | 0.7 | 0.4–1.3 |
| Diabetes | 10 (38.4) | 9.3 | 3.6–24.1 | 7.6 | 3.0–19.4 | 0 (–) | – | – | - | - | 4 (3.0) | 0.46 | 0.15–1.43 | 0.4 | 0.1–1.2 |
| Heart diseasec | 1 (3.0) | 0.6 | 0.1–4.7 | 0.5 | 0.1–4.1 | 0 (–) | – | – | - | - | 7 (4.2) | 0.84 | 0.32–2.18 | 0.7 | 0.3–1.7 |
| Stroke | 1 (2.1) | 1.5 | 0.2–11.0 | 1.0 | 0.1–7.3 | 0 (–) | – | – | - | - | 2 (1.5) | 1.0 | 0.23–4.32 | 0.8 | 0.2–3.3 |
| Asthma | 5 (29.2) | 5.5 | 1.69–17.5 | 5.4 | 1.9–15.9 | 2 (30.6) | 5.8 | 0.97–35.15 | 4.8 | 0.9–26.3 | 7 (6.9) | 0.98 | 0.36–2.61 | 0.5 | 0.2–1.1 |
| Arthritis/rheumatism | 6 (12.2) | 3.1 | 1.1–8.9 | 2.6 | 1.0–6.6 | 0 (–) | – | – | – | – | 2 (1.3) | 0.29 | 0.07–1.21 | 0.3 | 0.1–1.1 |
| Spine problemsc | 17 (56.2) | 6.3 | 2.0–19.7 | 4.2 | 1.6–11.3 | 6 (22.1) | 1.4 | 0.38–5.08 | 1.1 | 0.3–3.9 | 11 (27.3) | 1.85 | 1.1–3.2 | 1.7 | 1.0–3.0 |
| WMSDsd | 3 (6.0) | 2.1 | 0.5–8.9 | 1.9 | 0.5–7.9 | 1 (3.3) | 1.1 | 0.13–8.98 | 1.0 | 0.1–8.5 | 3 2.0 | 0.64 | 0.18–2.29 | 0.6 | 0.2–2.2 |
| Chronic headache | 11 (41.0) | 5.0 | 2.3–11.3 | 4.3 | 1.5–12.4 | 8 (34.3) | 3.8 | 1.01–14.2 | 2.4 | 0.6–9. 2 | 21 (17.7) | 1.56 | 0.91–2.68 | 1.2 | 0.7–2.1 |
| Chronic muscle pain | 17 (53.0) | 6.2 | 2.1–18.4 | 3.5 | 1.4–8.4 | 8 (43.6) | 4.2 | 1.15–15.7 | 2.6 | 0.6–11.2 | 26 (26.1) | 1.94 | 1.14–3.3 | 1.7 | 1.0–2.8 |
| Fibromyalgia | 2 (4.5) | 4.9 | 0.8–28.8 | 3.0 | 0.6–15.6 | 1 (2.7) | 2.9 | 0.38–22.7 | 1.5 | 0.2–14.2 | 0 (–) | – | – | – | – |
| Gastroesophageal reflux | 7 (16.9) | 5.0 | 1.6–15.8 | 4.7 | 1.6–13.7 | 3 (6.6) | 1.75 | 0.46–6.7 | 1.4 | 0.4–5.2 | 8 (8.3) | 2.3 | 0.89–5.7 | 2.1 | 0.9–5.1 |
| Irritable bowel syndrome | 0 (–) | – | – | – | – | 1 (3.3) | 3.2 | 0.42–24.7 | 2.0 | 0.2–17.3 | 2 (2.5) | 2.5 | 0.6–10.4 | 1.9 | 0.5–8.3 |
Model 1—Univariate Poisson regression; Model 2—Poisson regression adjusted by BMI, gender, race/skin color. Calculations of Relative Risk and 95% confidence intervals were adjusted for survey weights
Values in bold indicate statistically significant at a p-value < 0.05
BED Binge Eating Disorder (DSM-5), BN Bulimia Nervosa, RBE Recurrent Binge Eating—(≥ 1 binge eating episode/week in the last 3 months)
aThis variable was assessed with the question: "Has any doctor ever given you a diagnosis of (disease X)?"
bHeart disease (myocardial infarction, angina, heart failure or others)
cSpine problems such chronic back or neck pain, lumbago, sciatic pain, vertebra or disc trouble
dWork-related musculoskeletal disorders (WMSDs)